In July 2024, the FDA quietly approved one of the most significant changes in pediatric food allergy treatment in years: Palforzia — the only FDA-approved oral immunotherapy for peanut allergy — was approved for children as young as one year old. Previously, it had been approved only for ages 4 through 17. For parents of peanut-allergic toddlers in Burbank, Glendale, Pasadena, and across the Los Angeles area, that approval changed the answer to a question many families had been asking: "Is there anything we can actually do right now, or do we just wait and avoid?"

There is. And there are good reasons to think that for many families, doing it sooner rather than later is the better choice. At the Los Angeles Food Allergy Institute, we evaluate peanut-allergic toddlers for Palforzia and for other treatment paths. This guide walks through exactly what's involved — who qualifies, what the protocol looks like, what to expect at the first visit, what the daily routine becomes, what success at six and twelve months means in practice, and how to think about whether your child is a candidate.

Why the Toddler Approval Matters

For most of medical history, the standard advice for a child with a peanut allergy was strict avoidance, carry an epinephrine auto-injector, and hope they outgrow it. The data on outgrowing is sobering — only about 20% of children with peanut allergy outgrow it on their own. That meant the rest were expected to manage avoidance for life.

Two pieces of research changed the conversation. The first was the LEAP study, published in 2015, which showed that early introduction of peanut in high-risk infants dramatically reduced the development of peanut allergy in the first place. That study changed pediatric guidance worldwide and led to current recommendations for early peanut introduction in babies — something we cover in detail in our guide on safely introducing allergens to babies.

The second was the POSEIDON study, published in the New England Journal of Medicine Evidence in 2023. POSEIDON specifically tested Palforzia in 146 peanut-allergic children aged 1 to 3. It met both its primary and secondary efficacy endpoints, and the safety profile was acceptable. That data is what led the FDA to expand the approval to toddlers in July 2024.

Why does earlier intervention matter so much? The simplest framing comes from the immunology: a younger immune system is more flexible. The first few years of life are when the immune system is still calibrating what it considers a threat. Introducing controlled exposure to peanut protein during that window appears to produce better, faster, and more durable results than the same treatment started later. The POSEIDON results bear this out. For families with a child who's been diagnosed with a peanut allergy in the first three years of life, there's now a real, FDA-approved option to take advantage of that biological window.

Who Qualifies for Palforzia

The FDA approval covers patients ages 1 through 17 with a confirmed diagnosis of peanut allergy. A few things in that sentence matter.

• Confirmed diagnosis. Palforzia isn't appropriate for a suspected peanut allergy or for a positive skin prick test alone. The diagnosis needs to be confirmed clinically — typically through a combination of medical history, skin prick testing, blood testing for peanut-specific IgE, and where appropriate, a oral food challenge. The full diagnostic picture matters.
• Peanut only. Palforzia treats peanut allergy and nothing else. Children with multiple food allergies still benefit from Palforzia for the peanut component, but separate protocols (or different treatments like Xolair) are required for other allergens.
• Age 1 through 17. Initial Dose Escalation can begin at age 1. Children who turn 18 during treatment continue on Palforzia.
• REMS enrollment is required. Palforzia is only available through a restricted FDA program called the Palforzia Risk Evaluation and Mitigation Strategy (REMS). Both the family and the clinic must be enrolled before treatment can begin. Our Burbank clinic is REMS-certified.

There are also some patients for whom Palforzia isn't appropriate — children with uncontrolled asthma, a history of eosinophilic esophagitis (EoE), or certain other conditions. Those are clinical judgments made during the initial evaluation.

The Three-Phase Palforzia Protocol

Palforzia follows a standardized three-phase protocol. The structure is the same for every patient; some details differ slightly between the toddler dosing (ages 1-3) and the older child dosing (ages 4-17).

Phase 1: Initial Dose Escalation (Day 1)

The first day of Palforzia treatment happens entirely in the clinic. The child receives a series of increasing doses of peanut protein powder over the course of the day, each followed by a monitoring period to ensure tolerance.

• For toddlers (ages 1-3): 4 doses on Day 1, ranging from 0.5 mg to 3 mg of peanut protein.
• For children (ages 4-17): 5 doses on Day 1, ranging from 0.5 mg to 6 mg.

The full Initial Dose Escalation appointment is approximately 4 hours, including the monitoring time after each dose. The child stays in the clinic for at least an hour after the final dose so we can confirm the dose is tolerated. Most children get through Day 1 without significant issue; those who experience reactions are managed in the clinic, and we adjust the plan if needed.

Phase 2: Up-Dosing

After Day 1, the up-dosing phase begins. The child takes a daily dose of Palforzia at home, mixed into a small amount of cool or room-temperature soft food (applesauce, yogurt, pudding — the powder doesn't dissolve in liquid). Every two weeks or so, the family returns to the clinic for the next dose increase — that first dose at each new level is given in the clinic, observed for at least one hour, and then continued at home if tolerated.

The toddler protocol includes a 1 mg up-dose level that doesn't exist in the older child protocol. After that, the up-dosing schedule converges with the protocol for older children. The full up-dosing phase typically takes about 6 months. POSEIDON used a 22-week dose escalation, which is in the same range.

Each clinic up-dosing appointment is approximately 60 minutes. There are typically around 11 of these visits across the up-dosing phase.

Phase 3: Maintenance

Once the child reaches the 300 mg daily dose — equivalent to about one peanut — they enter maintenance. From there, the routine is straightforward: one 300 mg sachet of Palforzia powder mixed into soft food, taken once a day at home, ongoing.

Maintenance continues indefinitely. The peanut-avoidant diet continues alongside it — Palforzia is not a license to eat peanut butter sandwiches freely. The point of the maintenance dose is to keep the immune system desensitized so that accidental exposure to peanut produces a much smaller reaction than it would have before treatment.

What Daily Home Dosing Actually Looks Like

Many families ask what daily Palforzia dosing fits into a normal family schedule. Here's the practical picture:

• The dose is taken once a day, ideally at roughly the same time each day.
• The powder is mixed into a small amount of cool or room-temperature soft food. Common choices are applesauce, yogurt, pudding, or a similar smooth food. The food must be cool or room-temperature; heat can denature the protein.
• The child eats the dose-and-food mixture in one sitting.
• After taking the dose, the child should rest quietly for two hours — no vigorous exercise, no hot showers or baths, no exertion that significantly raises body temperature or heart rate. These factors can increase the chance of a reaction to the dose.
• A dose should not be taken on an empty stomach, when the child is sick, or when there's an active asthma flare.

The two-hour quiet period is the part most families find takes some adjustment. For toddlers, this often becomes part of the daily routine — dose with breakfast, then quiet play or screen time, then the day continues normally. It's a constraint, but a manageable one.

Common Side Effects in Toddlers

Honest answer: side effects are common with Palforzia, especially during the up-dosing phase. Most are mild and manageable, but families should know what to expect.

The most commonly reported side effects in toddlers ages 1 through 3 in the POSEIDON study and clinical practice include: cough, sneezing, runny nose, nasal congestion, throat irritation, wheezing, stomach pain, vomiting, diarrhea, itchy mouth, throat pain, hives, rash, itchy skin, and inflammation around the mouth. Most of these are mild and resolve quickly. Some can be managed with antihistamines or by adjusting the dose schedule.

There are more serious risks. Palforzia can cause anaphylaxis, which is why each new dose level starts in the clinic, why patients are observed for at least an hour after each in-clinic dose, and why every family on Palforzia has and knows how to use an epinephrine auto-injector. A small percentage of patients develop eosinophilic esophagitis (EoE) and need to stop treatment. The Palforzia REMS program exists specifically to manage these risks.

The honest bottom line: most toddlers experience some side effects, most are mild, most are manageable, and most families continue treatment successfully through the up-dosing phase. A minority of patients can't tolerate Palforzia, and stopping early is a normal outcome that doesn't reflect failure.

What Success Looks Like at 6 and 12 Months

It's worth being precise about what "success" with Palforzia actually means, because parents often have an inflated expectation that needs adjusting and a deflated expectation that needs correcting.

At 6 months

By the end of the typical 6-month up-dosing phase, a successful patient has reached the 300 mg maintenance dose and is taking it daily without significant issue. That 300 mg dose is equivalent to about one peanut. In practical terms: a child who would have reacted to a fraction of a peanut at the start of treatment can now tolerate a full peanut's worth of protein daily as a routine part of their diet.

This doesn't mean the child can eat peanut butter sandwiches. Avoidance continues. What it means is that the threshold for accidental exposure causing a reaction has been substantially raised.

At 12 months

In the POSEIDON study, after 12 months of treatment, the majority of toddlers on Palforzia could tolerate significantly higher amounts of peanut protein during a controlled food challenge than they could before treatment — and significantly more than the placebo group. The protective effect is real and measurable.

In real-world terms, what this looks like is families who used to live in fear of every birthday party, restaurant visit, and school snack now being able to navigate those situations with reasonable precautions rather than constant anxiety. Accidental exposure to a cookie that touched peanut butter no longer means an ER visit. Trace contamination from a shared kitchen no longer triggers a severe reaction. The allergy is still there — but the consequence of accidental exposure is dramatically smaller.

How to Know If Your Toddler Is a Candidate

If your child is between one and three years old and has been diagnosed with a peanut allergy, the practical question is: should you start a Palforzia evaluation now, or wait? A few patterns help orient the answer.

A Palforzia evaluation generally makes sense to schedule sooner if:

• Your child has been diagnosed with peanut allergy (clinically confirmed, not just a positive test).
• Your child does not have uncontrolled asthma, a history of EoE, or other contraindications.
• Your family is prepared for the time commitment — biweekly clinic visits during up-dosing, daily home dosing throughout.
• You're motivated by the toddler-window advantage — the immunological case for earlier intervention is real.

It might make sense to wait or consider alternatives if:

• Your child has multiple food allergies beyond peanut, in which case the conversation might also include Xolair as a way to handle the full picture.
• Your family schedule doesn't currently accommodate biweekly clinic visits.
• There are medical reasons identified during the initial evaluation that make Palforzia inappropriate.

The most useful thing about an evaluation isn't a yes-or-no on Palforzia. It's a clear picture of what's possible: Palforzia, OIT, Xolair, combination approaches, or waiting and watching. We compared the three options in detail in a separate post if you want to think through the broader landscape first.

The Bottom Line for LA Families

If you're a parent in Burbank, Glendale, Pasadena, Sherman Oaks, Studio City, North Hollywood, La Crescenta, or anywhere across the Los Angeles area, and your toddler has been diagnosed with a peanut allergy, the most important thing to know is that you don't have to wait until age four anymore. The FDA approval for ages 1 through 3 came in July 2024. The clinical data behind it is solid. The protocol is well-defined. And the earlier-is-better immunological case is real.

The next step is straightforward: a peanut allergy evaluation at our Burbank clinic. We'll confirm the diagnosis, review your child's specific situation, talk through Palforzia and any other appropriate options, and give you a clear recommendation. The evaluation is covered as a standard specialist visit under most major insurance plans.

Schedule a peanut allergy evaluation at the LAFAI Burbank clinic →

This article reflects publicly available information about Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] as of 2026, including the July 2024 FDA approval for ages 1 through 3 and the POSEIDON study findings published in the New England Journal of Medicine Evidence in 2023. It is educational and does not constitute medical advice. Palforzia carries a Boxed Warning for anaphylaxis and is available only through the Palforzia REMS program. A clinical evaluation with a board-certified allergist is required to determine whether Palforzia is appropriate for any individual patient.

‍